Artificial intelligence has changed the face of the healthcare industry. AI provides the tools to transform operations for greater efficiency while helping you better understand your patients. It’s simple in theory, but with game-changing results.
COVID-19 has obviously affected the industry, especially by disrupting clinical trials. This is a crucial moment for AI to play an important role in restoring the drug pipeline for pharmaceutical companies. And with data being increasingly vital in the life-sciences industry, AI is the only way to manage its enormous scope from both the patient and therapy perspectives.
Capgemini has kept a close eye on the trends surrounding AI for years. Most recently, we have been interested in the progress made in democratizing the high potential of AI and understanding the immediate impacts of COVID-19 on AI investments.
To explore these questions, the Capgemini Research Institute surveyed 950 organizations that are involved in ongoing AI initiatives and have at least one billion dollars in annual revenue. Our report examines what we discovered and the crucial factors organizations must consider to unlock the full potential of becoming an AI-powered enterprise.
Fill in the form below to download “The AI-powered enterprise” research report